Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Receivables - Other: 2014-2022

Historic Receivables - Other for Rockwell Medical (RMTI) over the last 5 years, with Sep 2022 value amounting to $7.4 million.

  • Rockwell Medical's Receivables - Other rose 22.05% to $7.4 million in Q3 2022 from the same period last year, while for Sep 2022 it was $7.4 million, marking a year-over-year increase of 22.05%. This contributed to the annual value of $5.9 million for FY2021, which is 41.76% up from last year.
  • According to the latest figures from Q3 2022, Rockwell Medical's Receivables - Other is $7.4 million, which was down 8.94% from $8.1 million recorded in Q2 2022.
  • Rockwell Medical's 5-year Receivables - Other high stood at $8.1 million for Q2 2022, and its period low was $5,122 during Q3 2019.
  • Moreover, its 3-year median value for Receivables - Other was $5.9 million (2021), whereas its average is $5.7 million.
  • In the last 5 years, Rockwell Medical's Receivables - Other slumped by 99.93% in 2019 and then spiked by 80,513.04% in 2020.
  • Rockwell Medical's Receivables - Other (Quarterly) stood at $7.0 million in 2018, then plummeted by 39.79% to $4.2 million in 2019, then decreased by 0.76% to $4.2 million in 2020, then soared by 41.76% to $5.9 million in 2021, then increased by 22.05% to $7.4 million in 2022.
  • Its last three reported values are $7.4 million in Q3 2022, $8.1 million for Q2 2022, and $7.1 million during Q1 2022.